BOSTON, Massachusetts, June 24, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that is translating the novel science of condensates into breakthrough […]

BOSTON, Massachusetts, January 11, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today […]

The Pharma Letter features an interview with our CEO Ameet Nathwani: “Dewpoint Therapeutics was founded on the ground-breaking realization that […]

BOSTON, Massachusetts, January 7, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today […]

HAMBURG, Germany and BOSTON, Nov. 7, 2023 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and […]

BOSTON and GLASGOW, September 12, 2023 – Dewpoint Therapeutics and Chemify today announced a partnership to develop a suite of digitally […]

Boston, Massachusetts March 22, 2023 – Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates […]

BOSTON, Nov. 14, 2022 — Dewpoint Therapeutics Inc. today announced the U.S. Patent and Trademark Office (USPTO) issued the patent “Methods of Characterizing […]

BOSTON, September 22, 2022 – Dewpoint Therapeutics, Inc. today announced biomolecular scientist Anthony (Tony) Hyman, a co-founder of Dewpoint Therapeutics and Director […]

BOSTON, May 25, 2022 — Dewpoint Therapeutics Inc., today announced the US Patent and Trademark Office (USPTO) issued the patent “Methods of […]

In June 2024, Lis Leiderman, M.D., MBA joined Dewpoint’s Executive Leadership Team as Chief Financial and Corporate Development Officer. With […]

At Dewpoint, we are working to unlock the full potential of condensate science to discover and develop life-changing treatments for […]

At Dewpoint we are embracing all forms of science from biology, chemistry and physics to data science and artificial intelligence […]

“I believe we are on our way towards a MYC c-mod, says Bede Portz, Dewpoint’s ovarian cancer program lead. Our […]